News
Media
All VideosMedical World NewsPodcastsWeekly RecapCure ConnectionsInsightsSpecial ReportNeurologyLive Peer ExchangeClinical Forum InsightsMedcastPeers & PerspectivesRoundtable DiscussionsShows & Podcasts
Conferences
Conference CoverageConference Listing
CME/CE
More
Partners
Publications
NeurologyLiveBridging the GapsInternational Journal of MS Care
Resources
Expert AuthorsFDA NewsFeaturesFellows' CornerFuture Leaders in NeurologyGiants of Multiple SclerosisInteractive ToolsJob BoardLive EventsNeurology ResourcesSponsoredVirtual Events

Subscribe

  • News
  • Media
  • Conferences
  • CME/CE
  • Partners
  • Publications
  • Resources
  • Subscribe
  • Dementia and Alzheimer Disease
  • Epilepsy
  • Genetic Disorders
  • Headache and Migraine
    • Migraine
  • MS and Demyelinating Disorders
    • NMOSD
    • Multiple Sclerosis
  • Movement Disorders
    • Parkinson Disease
    • Dyskinesia
  • Neuromuscular
    • Chronic Inflammatory Demyelinating Polyneuropathy
    • Muscular Dystrophy
    • Ataxia
  • Rare Diseases
  • Sleep Disorders
    • Narcolepsy
    • Excessive Daytime Sleepiness
    • Insomnia
  • Stroke
Spotlight -
Expert Authors|
FDA News|
Upcoming Live Events|
AANEM 2025|
AES 2025|
NSGC 2025
Advertisement

Olena Bueno, RN

Advertisement

Articles by Olena Bueno, RN

Jose Soria, MD  (Credit: The Neuron Clinic)

Challenges and Opportunities Bringing Lecanemab to Neurology Community Clinics 

ByJose Soria, MD,Olena Bueno, RN,Uriel Romero, MD,Claudia Asencio, MA,Kevin McGehrin, MD,Branko Huisa, MD
October 8th 2024

A group of experts from The Neuron Clinic shared their experience developing a novel inclusive clinical program to treat patients with early Alzheimer disease using lecanemab.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

    1

    Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1

    2

    sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis

    3

    Enhancing ALS Care Through Genetics, Biomarkers, and Clinical Trial Readiness: Brian Lin, PhD

    4

    FDA Approves Subcutaneous Copper Histidinate as First Treatment for Pediatric Menkes Disease

    5

    Phase 3 Data Readout of EMPEROR Study to Come Earlier, With FDA Submission Expected to Follow

    • About Us
    • Advisory Board
    • Editorial
    • Contact Us
    • Advertise
    • Contact MJH LS
    • Do Not Sell My Information
    • Terms and Conditions
    • Privacy
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    609-716-7777

    • Contagion Live
    • CGT Live
    • Neurology Live
    • HCP Live
    • Oncology Live
    • Contemporary Pediatrics
    • Contemporary OBGYN
    • Urology Times
    • The Educated Patient
    HCP Live
    Brand Logo

    © 2025 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us